Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


30.01.2023

1 Acta Histochem
1 Adv Sci (Weinh)
1 Bioeng Transl Med
2 Biomedicines
1 Biosensors (Basel)
1 Cancers (Basel)
1 Cell Death Dis
1 Clin Transl Oncol
2 Curr Oncol
1 Curr Opin Nephrol Hypertens
1 Eur J Radiol
2 Eur Urol
1 Eur Urol Oncol
1 Evid Based Complement Alternat Med
4 Front Genet
1 Front Mol Biosci
1 Front Oncol
1 Funct Integr Genomics
1 Heliyon
1 Histol Histopathol
1 Indian J Surg Oncol
4 Int J Mol Sci
2 J Clin Med
1 J Clin Oncol
1 J Clin Pathol
1 J Exp Clin Cancer Res
1 J Immunother Cancer
1 J Minim Access Surg
1 J Pathol
1 J Pers Med
1 J Transl Med
2 Medicina (Kaunas)
1 Minerva Pediatr (Torino)
3 Nihon Hinyokika Gakkai Zasshi
1 Nutrients
3 Pathol Res Pract
1 PeerJ
1 Pharmaceutics
1 Photodiagnosis Photodyn Ther
1 PLoS One
1 Sci Bull (Beijing)
1 Transl Oncol
6 Urol Int
1 Urol Oncol
1 Urology
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Histochem

  1. MLICKA A, Mlicki P, Niewiadomski P, Zielinska W, et al
    Synergistic effect of metformin and doxorubicin on the metastatic potential of T24 cells.
    Acta Histochem. 2023;125:151975.
    PubMed         Abstract available


    Adv Sci (Weinh)

  2. ZHANG Q, Liu S, Wang H, Xiao K, et al
    ETV4 Mediated Tumor-Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer.
    Adv Sci (Weinh). 2023 Jan 20:e2205613. doi: 10.1002/advs.202205613.
    PubMed         Abstract available


    Bioeng Transl Med

  3. ASHRAFIZADEH M, Zarrabi A, Karimi-Maleh H, Taheriazam A, et al
    (Nano)platforms in bladder cancer therapy: Challenges and opportunities.
    Bioeng Transl Med. 2022;8:e10353.
    PubMed         Abstract available


    Biomedicines

  4. VARELA M, Lopez M, Ingold M, Alem D, et al
    New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs.
    Biomedicines. 2023;11:199.
    PubMed         Abstract available

  5. BEJRANANDA T, Saetang J, Sangkhathat S
    Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment.
    Biomedicines. 2022;11:69.
    PubMed         Abstract available


    Biosensors (Basel)

  6. SONG FX, Xu X, Ding H, Yu L, et al
    Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer.
    Biosensors (Basel). 2023;13:106.
    PubMed         Abstract available


    Cancers (Basel)

  7. MONTEIRO-REIS S, Ferreira JPS, Pires RA, Lobo J, et al
    Bladder Wall Stiffness after Cystectomy in Bladder Cancer Patients: A Preliminary Study.
    Cancers (Basel). 2023;15:359.
    PubMed         Abstract available


    Cell Death Dis

  8. LI P, Mi Q, Yan S, Xie Y, et al
    Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-beta2 signaling axis.
    Cell Death Dis. 2023;14:59.
    PubMed         Abstract available


    Clin Transl Oncol

  9. GUO B, Wang Y, Liu W, Zhang S, et al
    Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Clin Transl Oncol. 2023;25:535-554.
    PubMed         Abstract available


    Curr Oncol

  10. ZALAY O, Yan M, Sigurdson S, Malone S, et al
    Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.
    Curr Oncol. 2022;30:19-36.
    PubMed         Abstract available

  11. YEN A, Shen C, Albuquerque K
    The New Kid on the Block: Online Adaptive Radiotherapy in the Treatment of Gynecologic Cancers.
    Curr Oncol. 2023;30:865-874.
    PubMed         Abstract available


    Curr Opin Nephrol Hypertens

  12. HAN DS, Johnson JP, Schulster ML, Shah O, et al
    Indications for and results of renal autotransplantation.
    Curr Opin Nephrol Hypertens. 2023;32:183-192.
    PubMed         Abstract available


    Eur J Radiol

  13. LAI AL, Law YM
    VI-RADS in bladder cancer: Overview, pearls and pitfalls.
    Eur J Radiol. 2023;160:110666.
    PubMed         Abstract available


    Eur Urol

  14. QUAN C, Chen J, Hu J
    Re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Eur Urol. 2023 Jan 24:S0302-2838(23)00020-9. doi: 10.1016/j.eururo.2022.
    PubMed        

  15. KLUMPER N, Holzel M, Eckstein M
    Reply to Jon Griffin. TIME for a Change? Multimarker Assessment of the Tumour Immune Microenvironment and Metastatic Site Biopsy to Improve Immunotherapy Response Prediction in Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2023 Jan 24:S0302-2838(23)00022-2. doi: 10.1016/j.eururo.2023.
    PubMed        


    Eur Urol Oncol

  16. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Eur Urol Oncol. 2023 Jan 18:S2588-9311(23)00004.
    PubMed         Abstract available


    Evid Based Complement Alternat Med

  17. AND ALTERNATIVE MEDICINE EC
    Retracted: Effect of Radical Laparoscopic Surgery and Conventional Open Surgery on Surgical Outcomes, Complications, and Prognosis in Elderly Patients with Bladder Cancer.
    Evid Based Complement Alternat Med. 2023;2023:9835627.
    PubMed         Abstract available


    Front Genet

  18. CAI J, Xie H, Yan Y, Huang Z, et al
    A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer.
    Front Genet. 2023;13:1082691.
    PubMed         Abstract available

  19. XIAO Y, Xu D, Jiang C, Huili Y, et al
    Telomere maintenance-related genes are important for survival prediction and subtype identification in bladder cancer.
    Front Genet. 2023;13:1087246.
    PubMed         Abstract available

  20. DENG H, Deng D, Qi T, Liu Z, et al
    An IFN-gamma-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts.
    Front Genet. 2023;13:1100317.
    PubMed         Abstract available

  21. TANTRAY I, Ojha R, Sharma AP
    Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.
    Front Genet. 2023;13:1051762.
    PubMed         Abstract available


    Front Mol Biosci

  22. MARTINS-LIMA C, Chianese U, Benedetti R, Altucci L, et al
    Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
    Front Mol Biosci. 2023;9:1070383.
    PubMed         Abstract available


    Front Oncol

  23. YU X, Luo B, Lin J, Zhu Y, et al
    Alternative splicing event associated with immunological features in bladder cancer.
    Front Oncol. 2023;12:966088.
    PubMed         Abstract available


    Funct Integr Genomics

  24. SHEN C, Yan Y, Yang S, Wang Z, et al
    Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Funct Integr Genomics. 2023;23:46.
    PubMed         Abstract available


    Heliyon

  25. ZHANG W, Yang F, Mao S, Wang R, et al
    Bladder cancer-associated microbiota: Recent advances and future perspectives.
    Heliyon. 2023;9:e13012.
    PubMed         Abstract available


    Histol Histopathol

  26. HUANG L, Shao W, Wang X, Li F, et al
    TBX3 stimulates proliferation and stem cell self-renewal in bladder carcinoma.
    Histol Histopathol. 2023;38:65-72.
    PubMed         Abstract available


    Indian J Surg Oncol

  27. TALWAR HS, Panwar VK, Mittal A, Kishore S, et al
    A Clinicopathological Correlation of Bladder Cancer in Young and Old Patients: Our Experience and Review of Literature.
    Indian J Surg Oncol. 2022;13:915-923.
    PubMed         Abstract available


    Int J Mol Sci

  28. DAS S, Hayden J, Sullivan T, Rieger-Christ K, et al
    The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.
    Int J Mol Sci. 2023;24:964.
    PubMed         Abstract available

  29. PEREZ-MONTIEL MD, Cerrato-Izaguirre D, Sanchez-Perez Y, Diaz-Chavez J, et al
    Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion.
    Int J Mol Sci. 2023;24:1092.
    PubMed         Abstract available

  30. LAZEWSKI D, Kucinska M, Potapskiy E, Kuzminska J, et al
    Enhanced Cytotoxic Activity of PEGylated Curcumin Derivatives: Synthesis, Structure-Activity Evaluation, and Biological Activity.
    Int J Mol Sci. 2023;24:1467.
    PubMed         Abstract available

  31. HUANG GK, Huang CC, Kang CH, Cheng YT, et al
    Genetic Interference of FGFR3 Impedes Invasion of Upper Tract Urothelial Carcinoma Cells by Alleviating RAS/MAPK Signal Activity.
    Int J Mol Sci. 2023;24:1776.
    PubMed         Abstract available


    J Clin Med

  32. YANG S, Zhou H, Feng C, Xu N, et al
    Web-Based Nomograms for Overall Survival and Cancer-Specific Survival of Bladder Cancer Patients with Bone Metastasis: A Retrospective Cohort Study from SEER Database.
    J Clin Med. 2023;12:726.
    PubMed         Abstract available

  33. CABALLERO JM, Gili JM, Pereira JC, Gomariz A, et al
    Risk Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain: A Case-Control Study.
    J Clin Med. 2023;12:728.
    PubMed         Abstract available


    J Clin Oncol


  34. Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 25:JCO2202889. doi: 10.1200/JCO.22.02889.
    PubMed        


    J Clin Pathol

  35. KULLMANN F, Strissel PL, Strick R, Stoehr R, et al
    Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.
    J Clin Pathol. 2023;76:126-132.
    PubMed         Abstract available


    J Exp Clin Cancer Res

  36. JIN M, Lu S, Wu Y, Yang C, et al
    Retraction Note: Hsa_circ_0001944 promotes the growth and metastasis in bladder cancer cells by acting as a competitive endogenous RNA for miR-548.
    J Exp Clin Cancer Res. 2023;42:32.
    PubMed        


    J Immunother Cancer

  37. VAN PUFFELEN JH, Novakovic B, van Emst L, Kooper D, et al
    Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
    J Immunother Cancer. 2023;11:e005518.
    PubMed         Abstract available


    J Minim Access Surg

  38. YONG Z, Ang L, Wen-Zhang Z, Xu-Dong W, et al
    Incidental gall bladder cancer in the laparoscopic treatment and magnetic resonance imaging era: A single institution experience.
    J Minim Access Surg. 2023 Jan 9. doi: 10.4103.
    PubMed         Abstract available


    J Pathol

  39. HOGLUND M, Bernardo C, Sjodahl G, Eriksson P, et al
    The Lund Taxonomy for Bladder Cancer Classification - From Gene Expression Clustering to Cancer Cell Molecular Phenotypes, and Back Again.
    J Pathol. 2023 Jan 26. doi: 10.1002/path.6062.
    PubMed         Abstract available


    J Pers Med

  40. YI L, Ai K, Li X, Li Z, et al
    Bone Metastasis in Bladder Cancer.
    J Pers Med. 2022;13:54.
    PubMed         Abstract available


    J Transl Med

  41. PAN J, Hong G, Zeng H, Liao C, et al
    An artificial intelligence model for the pathological diagnosis of invasion depth and histologic grade in bladder cancer.
    J Transl Med. 2023;21:42.
    PubMed         Abstract available


    Medicina (Kaunas)

  42. TRIFANESCU OG, Gales LN, Paun MA, Motas N, et al
    Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?
    Medicina (Kaunas). 2022;59:50.
    PubMed         Abstract available

  43. NIKIC P, Dragicevic D, Jerotic D, Savic S, et al
    Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness.
    Medicina (Kaunas). 2023;59:131.
    PubMed         Abstract available


    Minerva Pediatr (Torino)

  44. KLEANTHOUS K, Alexopoulou E, Papadopoulos I, Mazioti A, et al
    Asymptomatic bladder neurofibroma in neurofibromatosis type I.
    Minerva Pediatr (Torino). 2022;74:799-801.
    PubMed        


    Nihon Hinyokika Gakkai Zasshi

  45. TANABE T, Osawa T, Hotta K, Iwami D, et al
    [TREATMENT OF BLADDER UROTHELIAL CARCINOMA WITH LUNG METASTASIS AFTER RENAL TRANSPLANTATION].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:37-41.
    PubMed         Abstract available

  46. IMAMURA T, Miyachi S, Horiuchi E, Ikeda T, et al
    [A CASE OF PRIMARY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA OF THE URINARY BLADDER].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:28-32.
    PubMed         Abstract available

  47. KONDO Y, Takayama T
    [STUDY OF URINATION TREATMENT AFTER BCG INTRAVESICAL INSTILLATION THERAPY].
    Nihon Hinyokika Gakkai Zasshi. 2022;113:12-15.
    PubMed         Abstract available


    Nutrients

  48. RU R, Chen G, Liang X, Cao X, et al
    Sea Cucumber Derived Triterpenoid Glycoside Frondoside A: A Potential Anti-Bladder Cancer Drug.
    Nutrients. 2023;15:378.
    PubMed         Abstract available


    Pathol Res Pract

  49. PATWARDHAN PP, Quiroga-Garza GM
    Extramammary paget disease of the penoscrotal region.
    Pathol Res Pract. 2023;241:154283.
    PubMed         Abstract available

  50. KANG SY, Heo YJ, Kwon GY, Lee J, et al
    Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.
    Pathol Res Pract. 2023;241:154233.
    PubMed         Abstract available

  51. EL-MAHDY HA, Elsakka EGE, El-Husseiny AA, Ismail A, et al
    miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay - A review.
    Pathol Res Pract. 2023;242:154316.
    PubMed         Abstract available


    PeerJ

  52. WAN B, Ma N, Lu W
    Mendelian randomization investigation identified the causal relationship between body fat indexes and the risk of bladder cancer.
    PeerJ. 2023;11:e14739.
    PubMed         Abstract available


    Pharmaceutics

  53. YU C, Wang S, Lai WF, Zhang D, et al
    The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment.
    Pharmaceutics. 2023;15:211.
    PubMed         Abstract available


    Photodiagnosis Photodyn Ther

  54. KOBAYASHI K, Matsuyama H, Oka S, Nakamura K, et al
    Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2023;41:103294.
    PubMed         Abstract available


    PLoS One

  55. DIAS HF, Mochizuki Y, Kuhtreiber WM, Takahashi H, et al
    Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies.
    PLoS One. 2023;18:e0276423.
    PubMed         Abstract available


    Sci Bull (Beijing)

  56. XIANG L, Zeng Q, Liu J, Xiao M, et al
    MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
    Sci Bull (Beijing). 2021;66:1773-1788.
    PubMed         Abstract available


    Transl Oncol

  57. LIU HP, Jia W, Kadeerhan G, Xue B, et al
    Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature.
    Transl Oncol. 2023;29:101629.
    PubMed         Abstract available


    Urol Int

  58. KORKES F, Timoteo F, Baccaglini W, Glina F, et al
    Postoperative Mortality Rate after Radical Cystectomy: A Systematic Review of Epidemiologic Series.
    Urol Int. 2023;107:96-104.
    PubMed         Abstract available

  59. ZANG Z, Kesavan NR, Esuvaranathan K
    UBC(R)Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population.
    Urol Int. 2023;107:29-34.
    PubMed         Abstract available

  60. SCHNEIDEWIND L, Drager DL, Rossberg V, Nolting J, et al
    Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival.
    Urol Int. 2023;107:80-86.
    PubMed         Abstract available

  61. MICHAEL KGFT, Ravindranath N, Michael S, German A, et al
    Optimizing Upper-Tract Imaging for Non-Visible Haematuria.
    Urol Int. 2023;107:23-28.
    PubMed         Abstract available

  62. ZHANG Y, Ding H, Zhang Y, Tian J, et al
    Is Anti-Reflux Anastomosis an Advantage in an Orthotopic Ileal Neobladder? A Systematic Review and Meta-Analysis.
    Urol Int. 2023;107:1-14.
    PubMed         Abstract available

  63. EISMANN L, Bohn L, Buchner A, Casuscelli J, et al
    Age and ECOG Performance Status as Predictors of Survival of Patients with Upper Urinary Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.
    Urol Int. 2023;107:72-79.
    PubMed         Abstract available


    Urol Oncol

  64. ALJABERY F, Shabo I, Saudi A, Holmbom M, et al
    The emerging role of cell cycle protein p53 expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer.
    Urol Oncol. 2023 Jan 24:S1078-1439(22)00490.
    PubMed         Abstract available


    Urology

  65. GOLZY M, Rosen G, Kruse RL, Hooshmand K, et al
    Holistic assessment of quality of life predicts survival in older patients with bladder cancer.
    Urology. 2023 Jan 17:S0090-4295(23)00045-6. doi: 10.1016/j.urology.2022.
    PubMed         Abstract available


    World J Urol

  66. HEROUT R, Baunacke M, Flegar L, Borkowetz A, et al
    Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019.
    World J Urol. 2023;41:127-133.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: